Biotech Stocks Reviews
- Duchenne Muscular Dystrophy KOL Investor Call
Thu, Dec 5
On Wednesday December 4th, 2024 PropThink hosted a live webinar with 3 incredible Key Opinion Leaders · more » - Obesity & PD-1: History Doesn’t Repeat But It Rhymes
Mon, Dec 2
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar · more » - IL-18 Names Picking Up Interest in Cancer
Tue, Mar 12
One of the names we wrote about back in mid-December as a trade due to its ample cash position and · more » - GLP & MASH Names Heating Up With More Data Announcements
Mon, Mar 11
In a prior note, we covered the impact that GLP-1 drug class would have on related markets. On this · more » - Transcript of KOL Call: Urologist Talks Bladder Cancer and Lasting Side Effects
Tue, Feb 27
Participants PropThink Dr. Michael Chancellor, KOL Jonathan Kaufman, Lipella CEO PropThink Good · more » - Modular Medical Submits 510(k) for Insulin Patch Pump
Mon, Jan 22
Modular Medical (MODD)announcedthe 510(k) submission of their MODD1 insulin pump to the FDA last week.On · more » - 2024 Trends to Watch as Biotech Makes Comeback
Tue, Jan 16
Biotech has roared back and seen a strong start to the new year. Since November, in less than 3 months, · more » - Big Pharma’s M&A Strategy Is Likely to Stay the Same in 2024
Sat, Dec 23
Bristol Myers Squibb announced the acquisition of Karuna (KRTX) for $14B to add a first-in-class · more » - Awaited Catalysts in Obesity & Radiopharmaceutical Markets Miss Expectations
Tue, Dec 19
Yesterday, both obesity and radiopharmaceuticals had year end catalysts that unfortunately did not meet · more »